UK – BMS’ Opdivo wins new NICE lung cancer backing

NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for patients with squamous or non-squamous non-small-cell lung cancer (NSCLC).

First-line of treatment for locally advanced stages of the disease is currently either chemotherapy or a PD-1 or PD-L1 inhibitor; Opdivo has been endorsed for patient groups treated with chemotherapy only…